Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

CHANCES ARE, ONE out of five of you reading this will be diagnosed with skin cancer by the time you hit age 70. As the most ...

Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.

Smoking, alcohol consumption and betel nut chewing are some of the lifestyle factors that have been linked to head and neck ...